Company Snapshot: Prothena Corporation

PRTA
Last	Change	Volume	High	Low

Company Overview

Prothena Corporation plc, a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of novel antibodies for the treatment of various diseases associated with protein misfolding or cell adhesion. Its product pipeline includes NEOD001, a product candidate in Phase 1 clinical trial to target AL and AA forms of amyloidosis; PRX002 for the treatment of Parkinson’s disease and related synucleinopathies; and PRX003 for the treatment of inflammatory disease and metastatic cancers. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein. Prothena Corporation plc was incorporated in 2012 and is headquartered in Dublin, Ireland.

Client News

1. Apr 15 2024 Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma
2. Mar 5 2024 Prothena to Participate in Upcoming Healthcare Conferences
3. Mar 4 2024 Prothena Appoints David Ford to Newly Created Chief People Officer Position
4. Feb 21 2024 Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate
5. Feb 15 2024 Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights